Sona Nanotech, Inc. · CSE:SONA
Sona Nanotech — Investor Presentation (April 2024)
21 slides from Sona Nanotech's investor presentation, Apr 12, 2024
Slide 1: Empowering Immuno-Oncology Therapies By Stimulating the Immune System
Empowering Immuno-Oncology Therapies By Stimulating the Immune System: A Novel 1-2 Punch Against Cancer April 2024 sonanano.com CSE: SONA | OTCQB: SNANF
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking information under Actual results may differ materially from those set forth in applicable securities law. All information that addresses this presentation due to risks and uncertainties affecting Sona activities or developments tha
Slide 3: Using Proprietary, Uniquely Biocompatible Nanotechnology for a More Effective and Gentler Cancer Therapy
Using Proprietary, Uniquely Biocompatible Nanotechnology for a More Effective and Gentler Cancer Therapy That Enables Immunology Sona’s Proprietary Technology Sona’s Gold Nanorod Advantages • Patented*, biocompatible, Uniquely Biocompatible: • Sona surfactant uses no toxic CTAB ** proprietary gold n
Slide 4: Immuno-Oncology Therapies With Chemo Can Vastly Improve Survival Rates Vs. Chemo Alone
Immuno-Oncology (“IO”) Therapies With Chemo Can Vastly Improve Survival Rates Vs. Chemo Alone 5yr Overall Survial Rate In a recent Merck study, 20% their blockbuster IO 18% product Keytruda 16% increased five-year 14% survival rates by 12% ~81% 10% Named ‘Breakthrough of 8% the Year’ in 2013 by 6% 4
Slide 5: IO Success Can Be Constrained If The Tumor Antigens Presented Are Too Weak
IO Success Can Be Constrained If The Tumor Antigens Presented Are Too Weak To Elicit A Strong Immune Response Sources of Immunotherapy Resistance 1. Weak tumor antigen or loss of tumor-antigen More of a good expression thing isn’t necessarily better: 2. Upregulation of immune-checkpoint molecules Ad
Slide 6: Many Unexposed Antigens Exist in Tumors But How Can We Cause Them to be Presented
Many Unexposed Antigens Exist in Tumors But How Can We Cause Them to be Presented to the Immune System? Heating cancer cells gently causes them to die by apoptosis which causes the release of neo-antigens Sona’s therapy primes the tumor microenvironment to present neo-antigens, thereby enabling immu
Slide 7: The U.S. Market for Immuno-Oncology Therapy Drugs For Solid Cancers Is Worth $31 Billion
The U.S. Market for Immuno-Oncology Therapy Drugs For Solid Cancers Is Worth $31 Billion Top Immunotherapy Drugs by 2021 Sales (USD Billions) $- $2.0 $4.0 $6.0 $8.0 $10.0 $12.0 $14.0 $16.0 $18.0 $20.0 Keytruda (Merck) Opdivo (BMS) Tecentriq (Roche) Imfinzi (AstraZeneca) Yervoy (BMS) Raising response
Slide 8: Sona's Targeted Hyperthermia Therapy Applies NIR Light to Nanorod-Saturated Tumors
Sona’s Targeted Hyperthermia Therapy (THT) Applies NIR Light to Nanorod-Saturated Tumors To Heat Them From the Inside Out, Gently A Two Device System 1. 2. Inject Biocompatible Shine NIR Light Tuned Delivering a 1-2 Gold Nanorods Intratumorally to 850nm on Tumor Punch: 1. Heat causes cancer cell apo
Slide 9: THT's Hyperthermia Approach Heats Tumors to 41-48 °C
THT’s ‘Hyperthermia’ Approach Heats Tumors to 41-48 °C – Enough to Kill Cancer Cells, But Not Enough to Harm Healthy Cells . Cancer cell death by apoptosis Apoptosis: A type of cell death in which a series of molecular steps in a cell lead to its death. This is one method the body uses to get rid of
Slide 10: Sona's THT Therapy is Efficient and Selective in its Treatment
While Cancer Cell Death by Apoptosis Can Be Stimulated In a Variety of Ways, Sona’s THT Therapy is Efficient and Selective in its Treatment Rationale for Sona’s Targeted Hyperthermia Therapy (THT) • Gold nanorods (GNRs) are the most efficient gold nanoparticles at converting light energy into heat p
Slide 11: Sona's THT Therapy is Proprietary And Will Benefit From IP Protection
Sona’s THT Therapy is Proprietary And Will Benefit From IP Protection Sona’s Four Sources of IP Advantage Patents: Two Device System: • Method for Manufacture of Biocompatible Gold Nanorods • Once approved by regulators, Sona’s light device may • Issued: South Korea; Pending: PCT, USA, Canada, EU, C
Slide 12: THT Concept is Backed By Science; Now Relies On Preclinical Development Work to Advance
THT Concept is Backed By Science; Now Relies On Preclinical Development Work to Advance Previously Done/Approved: Sona To Do: - Heat used to kill cancer cells 1. Deliver infrared light device that can monitor temperature in real time - Photothermal treatment using infrared light devices 2. Preclinic
Slide 13: Development of THT Guided By A Panel Of Leading Physicians And Multiple FDA Interactions
Sona’s Development of THT Has Benefited From The Guidance Of A Panel Of Leading Physicians In The U.S. And Multiple FDA Interactions Stakeholder Engagement EXCITE International Panel Members: - Three surgical oncologists from leading U.S. cancer centres - Four physicians representing different U.S.
Slide 14: Sona Has Engineered the Right 'Gene Pool' to Develop Its Cancer Therapy
Sona Has Engineered the Right ‘Gene Pool’ to Develop Its Cancer Therapy Board Mark Lievonen Walter Strapps PhD Neil Fraser Jim Megann Chairman Director Director Director o Led vaccine maker Sanofi- o CEO of Khosla Ventures o Led Medtronic Canada for ~20 o 25 years of experience in Pasteur to a billi
Slide 15: Building the Safety and Efficacy Data Required by Regulators for a First in Human Study
Building the Safety and Efficacy Data Required by Regulators for a ‘First in Human’ Pivotal Phase 1 Clinical Study Research Current Efficacy Study at Dalhousie Study University: Evaluation of Sona Nanotech’s Gold Nanoparticle-Mediated Photothermal Therapy in Combination with Intralesional Immune Mod
Slide 16: Research Study Background – Premises
Research Study Background – Premises Research Study Cancer cells are Sona’s GNRs can be Immunotherapy is the inherently susceptible activated in precise leading-edge in cancer to therapeutic anatomic locations to treatment, but alone hyperthermic therapy cause THT induced has demonstrated a (THT) st
Slide 17: Research Study Background – Metrics of Success
Research Study Background – Metrics of Success Research Study Success Will Be Assessed By The Extent To Which: Tumor Shrinkage Enhanced Immune Abscopal Effects are Response Observed • THT causes tumor • Use of THT with certain • Immune responses created in volume reduction in immunotherapies is remo
Slide 18: Data Shows Synergistic Effect of Combining Sona's THT and Standard Immunotherapy Agent IL-2
Data Shows Synergistic Effect of Combining Sona’s THT and Standard Immunotherapy Agent IL-2 Research Study Research Study Background – Initial Results (Triple Negative Breast Cancer Mouse Tumor Model, n=6) Tumor Volume Tumor Volume (without error bars) (with error bars) A single dose of THT causes r
Slide 19: Moving Quickly Towards Pre-clinical Studies and Regulatory Filings
Moving Quickly Towards Pre-clinical Studies and Regulatory Filings 1. Selection of pre-clinical study partners, plans and initial safety study results • Utilizing pre-existing research & advisory groups to conduct studies in the most cost-effective ways 2. Panel of leading EXCITE International exper
Slide 20: Improving Immuno-Oncology Drug Response Rates Could Substantially Decrease Mortality Rates
Improving Immuno-Oncology Drug Response Rates Could Substantially Decrease Mortality Rates Immunotherapy Response Rate by Cancer Type 45% 40% 35% 30% 25% Study average = 21% 20% 15% 10% 5% 0% …And offer greater hope to the two million people expected to be diagnosed with cancer each year Sources: CA
Slide 21: Thank you
BIOCOMPATIBLE GNR GOLD NANOROD TECHNOLOGY Thank you David Regan david@sonanano.com CEO Sona Nanotech Inc. +1 902 448 1416 CSE: SONA | OTCQB: SNANF sonanano.com 21